Conclusion of an annex to the investment agreement regarding the acquisition of new shares in the Company for a contribution of approximately PLN 220 million.
Current report no . : 59/2022
Date: October 20, 2022
Legal basis: Article 17 para. 1 of MAR – confidential information
With reference to the current report No. 55/2022 on the conclusion of an investment agreement regarding the acquisition of new shares in the Company for a contribution in the amount of approx. PLN 220 million (PLN 44.27 per share, the Management Board of Medicalgorithmics SA (the “Company”) informs that on 20 October 2022, between the Company and Biofund Capital Management LLC based in Miami (USA) (” Biofund “), an annex was concluded to the agreement, the subject of which is the acquisition of 4,976,384 shares of the Company in the increased share capital, i.e. 49.99% of votes for the general meeting of the Company by Biofund (“Agreement”) (“Annex”).
The subject of the Annex is the obligation of the Company to ensure that the agenda of the next General Meeting of Shareholders will include voting on the resolutions appointing Mr. Krzysztof Siemionow and Mr. David Cash to the Supervisory Board. Also it indicates that the failure to appoint Mr. Paweł Lewicki as a member of the Supervisory Board Lewicki ( as one of the candidates for the Council Supervisory Board in accordance with the records Of the Agreement ) or Mr. Krzysztof Siemionow will entitle Biofund to use the possibility of withdrawing from the Agreement.